Leerink Swann Maintains an 'Outperform' on InterMune (ITMN); Lowering PT on Delays in Expected Esbriet Launch
Tweet Send to a FriendGet Alerts ITMN Hot Sheet
Price: $9.99 -3.01%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ITMN Now!
Leerink Swann maintains an 'Outperform' on InterMune Inc. (NASDAQ: ITMN) price target lowered from $37 to $27.
Analyst, Jonathan Eckard, said, "We are lowering our 12-month valuation on ITMN shares to $27, reflecting the delays in expected Esbriet launch in several EU countries and in the US, as well as more modest assumptions on German ramp-up. We reach our $27 valuation using a DCF analysis that assumes sales of Esbriet in Europe and probability-weighted US sales (at 65%) with IP protection only from the respective 10- and 7-years of orphan drug exclusivity. This DCF uses an 11% discount rate that we believe is appropriate given the inclusion of probability-weighted sales."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $15.28 yesterday, with a 52 week range of $10.67-$51.71.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jonathan Eckard, said, "We are lowering our 12-month valuation on ITMN shares to $27, reflecting the delays in expected Esbriet launch in several EU countries and in the US, as well as more modest assumptions on German ramp-up. We reach our $27 valuation using a DCF analysis that assumes sales of Esbriet in Europe and probability-weighted US sales (at 65%) with IP protection only from the respective 10- and 7-years of orphan drug exclusivity. This DCF uses an 11% discount rate that we believe is appropriate given the inclusion of probability-weighted sales."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $15.28 yesterday, with a 52 week range of $10.67-$51.71.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Cisco (CSCO) PT Raised to $26.50 at Nomura
- Topeka Capital Raises Google (GOOG) Target to $999, Co. on 'Forefront of Innovation'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
